Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Cardiff Oncology (CRDF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intellia Therapeutics (NTLA – Research Report) and Cardiff Oncology (CRDF – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Intellia Therapeutics (NTLA)
William Blair analyst Myles Minter reiterated a Hold rating on Intellia Therapeutics today. The company’s shares closed last Tuesday at $15.10.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intellia Therapeutics with a $14.27 average price target, representing a -13.6% downside. In a report issued on January 15, TipRanks – PerPlexity also upgraded the stock to Hold with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cardiff Oncology (CRDF)
Craig-Hallum analyst Albert Lowe maintained a Buy rating on Cardiff Oncology today. The company’s shares closed last Tuesday at $1.90.
According to TipRanks.com, Lowe is a 4-star analyst with an average return of
Currently, the analyst consensus on Cardiff Oncology is a Strong Buy with an average price target of $13.67.
